Valuation
- Market cap
- 8,748,446,000
- Revenue TTM
- $42,280,000
- Net income TTM
- $-173,420,000
- PE ratio
- 0.00
- Forward PE
- 872.73
- Profit margin
- -410.17%
- Debt to equity
- 0.87
Trading
- Volume
- 1,871,900
- Avg volume
- 1,571,794
- Day's range
- $106.81 – $106.93
- Shares out
- 81,830,000
- Stochastic %K
- 97%
- Beta
- 0.05
- Analysts
- Sell
- Price target
- $106.00
Company profile
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as w...
Show more
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 44 20 3283 4200
- Website
- https://www.veronapharma.com
- Address
- 3 More London Riverside, London, United Kingdom
Latest news
No headlines yet.
